Administer: Growth on hold pending Sarastia - Evli
This is a third party research report and does not necessarily reflect our views or values
Administer reports Q4 figures on March 4. We expect net sales to have declined slightly in the challenging market, while EBITDA should improve supported by previously implemented cost-saving measures. For 2026, much will depend on Sarastia.